SAN DIEGO, April 27, 2011 /PRNewswire/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the
Deutsche Bank 36th Annual Healthcare Conference on Wednesday, May 4, 2011 at 12:15 p.m. ET / 9:15 a.m.
PT in Boston. Mark Foletta, senior vice president, finance and
chief financial officer at Amylin Pharmaceuticals, will provide a
corporate overview.
The presentation will be webcast live through the "Investors"
section of Amylin's corporate website at www.amylin.com, and a
recording will be made available on the website following the
event. To access the live webcast, please log on to Amylin's site
approximately fifteen minutes prior to the presentation to register
and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California. Further
information about Amylin Pharmaceuticals is available at
www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.